NSE BSE
dr. reddy's laboratories stock

Dr. Reddy's Laboratories Share Price

- - (%)
Sector: -

881

500124

DRREDDY

img img img img
No Data Available

Dr. Reddy's Laboratories Performance

Day Range

Low5953.50 High6064.00
6016.10

52 Week Range

Low 4384.05 High 6505.90
6016.10

Open Price

5975.00

Prev. Close

5942.85

Volume (Shares)

333457.00

Total traded value

20061.10

Upper Circuit

6537.10

Lower Circuit

5348.60

Note: The current prices & values are delayed, Login to your account for live updates.

Dr. Reddy's Laboratories Fundamentals


(Standalone)

Market Cap (Cr) 100184.80
PE Ratio (TTM) 25.21
Book Value / Share 1361.85
Beta 0.46
ROE 13.46%
EPS (TTM) 238.56
Dividend Yield 0.66%
Net Profit Qtr (Cr) 475.20

Dr. Reddy's Laboratories Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars DEC 2023 (Values in Cr)
Revenue 4083.10
Operating Expense 3698.70
Net Profit 475.20
Net Profit Margin (%) 11.63
Earnings Per Share (EPS) 28.55
EBITDA 883.90
Effective Tax Rate (%) 24.79
Particulars SEP 2023 (Values in Cr)
Revenue 4819.10
Operating Expense 3461.20
Net Profit 1192.60
Net Profit Margin (%) 24.74
Earnings Per Share (EPS) 71.68
EBITDA 1852.19
Effective Tax Rate (%) 25.49
Particulars JUN 2023 (Values in Cr)
Revenue 5420.10
Operating Expense 3451.30
Net Profit 1639.40
Net Profit Margin (%) 30.24
Earnings Per Share (EPS) 98.66
EBITDA 2461.29
Effective Tax Rate (%) 26.13
Particulars MAR 2023 (Values in Cr)
Revenue 4537.80
Operating Expense 3732.20
Net Profit 672.40
Net Profit Margin (%) 14.81
Earnings Per Share (EPS) 40.49
EBITDA 1175.90
Effective Tax Rate (%) 28.20
Particulars DEC 2022 (Values in Cr)
Revenue 3879.60
Operating Expense 3464.10
Net Profit 324.60
Net Profit Margin (%) 8.36
Earnings Per Share (EPS) 19.54
EBITDA 726.50
Effective Tax Rate (%) 33.05
Particulars MAR 2023 (Values in Cr)
Revenue 16899.10
Operating Expense 13687.80
Net Profit 2612.80
Net Profit Margin (%) 15.46
Earnings Per Share (EPS) 157.37
EBITDA 4806.10
Effective Tax Rate (%) 32.41
Particulars MAR 2022 (Values in Cr)
Revenue 14315.30
Operating Expense 12663.40
Net Profit 1623.20
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 97.85
EBITDA 3076.10
Effective Tax Rate (%) 27.00
Particulars MAR 2021 (Values in Cr)
Revenue 13281.40
Operating Expense 11094.00
Net Profit 2186.40
Net Profit Margin (%) 16.46
Earnings Per Share (EPS) 131.84
EBITDA 3937.89
Effective Tax Rate (%) 28.46
Particulars MAR 2020 (Values in Cr)
Revenue 11803.00
Operating Expense 9817.80
Net Profit 2937.70
Net Profit Margin (%) 24.88
Earnings Per Share (EPS) 177.23
EBITDA 3612.80
Effective Tax Rate (%) -5.83
Particulars MAR 2019 (Values in Cr)
Revenue 10572.90
Operating Expense 9163.19
Net Profit 1277.30
Net Profit Margin (%) 12.08
Earnings Per Share (EPS) 76.98
EBITDA 2538.10
Effective Tax Rate (%) 24.89
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1405.34
ROE % 21.21
ROCE % 25.99
Total Debt to Total Equity 0.11
EBITDA Margin 30.16
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.21
ROE % 11.84
ROCE % 14.46
Total Debt to Total Equity 0.17
EBITDA Margin 20.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1072.02
ROE % 11.74
ROCE % 15.29
Total Debt to Total Equity 0.16
EBITDA Margin 22.10
Particulars MAR 2020 (Values in Cr)
Book Value / Share 944.61
ROE % 13.68
ROCE % 10.95
Total Debt to Total Equity 0.20
EBITDA Margin 17.97
Particulars MAR 2019 (Values in Cr)
Book Value / Share 848.02
ROE % 14.66
ROCE % 13.40
Total Debt to Total Equity 0.34
EBITDA Margin 23.04
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1236.56
ROE % 13.46
ROCE % 18.82
Total Debt to Total Equity 0.06
EBITDA Margin 28.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1111.56
ROE % 9.19
ROCE % 11.63
Total Debt to Total Equity 0.10
EBITDA Margin 21.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1032.48
ROE % 11.50
ROCE % 15.04
Total Debt to Total Equity 0.08
EBITDA Margin 25.97
Particulars MAR 2020 (Values in Cr)
Book Value / Share 920.13
ROE % 21.08
ROCE % 18.48
Total Debt to Total Equity 0.09
EBITDA Margin 30.49
Particulars MAR 2019 (Values in Cr)
Book Value / Share 767.33
ROE % 10.43
ROCE % 12.41
Total Debt to Total Equity 0.15
EBITDA Margin 23.89
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1730.20
Total Assets 32285.10
Total Liabilities 32285.10
Total Equity 23286.10
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 13.96
Return on Capital (%) 18.47
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2419.20
Total Assets 29746.90
Total Liabilities 29746.90
Total Equity 19212.40
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 7.33
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2078.80
Total Assets 26616.80
Total Liabilities 26616.80
Total Equity 17641.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 7.33
Return on Capital (%) 9.6
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 205.30
Total Assets 23225.30
Total Liabilities 23225.30
Total Equity 15598.80
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 8.72
Return on Capital (%) 11.66
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 222.80
Total Assets 22465.60
Total Liabilities 22465.60
Total Equity 14023.60
Share Outstanding 166065948
Price to Book Ratio 3.62
Return on Assets (%) 8.67
Return on Capital (%) 11.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 645.80
Total Assets 25374.80
Total Liabilities 25374.80
Total Equity 20474.20
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 10.29
Return on Capital (%) 12.76
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2030.50
Total Assets 24495.60
Total Liabilities 24495.60
Total Equity 18336.20
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 6.62
Return on Capital (%) 7.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1646.50
Total Assets 21629.60
Total Liabilities 21629.60
Total Equity 16983.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 10.10
Return on Capital (%) 12.04
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.20
Total Assets 19475.80
Total Liabilities 19475.80
Total Equity 15191.90
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 15.08
Return on Capital (%) 18.07
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 113.20
Total Assets 16247.50
Total Liabilities 16247.50
Total Equity 12684.10
Share Outstanding 166065948
Price to Book Ratio 3.62
Return on Assets (%) 7.86
Return on Capital (%) 9.41
Particulars MAR 2023 (Values in Cr)
Net Income 6048.50
Cash from Operations 6958.90
Cash from Investing -4137.30
Cash from Financing -2686.10
Net change in Cash -935.90
Free Cash Flow 8091.20
Particulars MAR 2022 (Values in Cr)
Net Income 3061.40
Cash from Operations 3554.50
Cash from Investing -2638.70
Cash from Financing -242.20
Net change in Cash -70.10
Free Cash Flow 5020.50
Particulars MAR 2021 (Values in Cr)
Net Income 2883.50
Cash from Operations 4141.90
Cash from Investing -2266.00
Cash from Financing -29.80
Net change in Cash 1274.50
Free Cash Flow 5116.00
Particulars MAR 2020 (Values in Cr)
Net Income 1885.70
Cash from Operations 3694.60
Cash from Investing -492.30
Cash from Financing -2515.90
Net change in Cash -24.10
Free Cash Flow 4179.20
Particulars MAR 2019 (Values in Cr)
Net Income 2335.80
Cash from Operations 3354.50
Cash from Investing -772.70
Cash from Financing -2132.60
Net change in Cash -34.90
Free Cash Flow 4050.00
Particulars MAR 2023 (Values in Cr)
Net Income 3866.00
Cash from Operations 5835.60
Cash from Investing -3447.60
Cash from Financing -2696.90
Net change in Cash -1091.60
Free Cash Flow 6835.80
Particulars MAR 2022 (Values in Cr)
Net Income 2223.80
Cash from Operations 1827.50
Cash from Investing -2038.00
Cash from Financing 505.50
Net change in Cash -193.80
Free Cash Flow 3138.80
Particulars MAR 2021 (Values in Cr)
Net Income 3056.20
Cash from Operations 3962.20
Cash from Investing -1458.00
Cash from Financing -794.30
Net change in Cash 1261.90
Free Cash Flow 4819.70
Particulars MAR 2020 (Values in Cr)
Net Income 2775.80
Cash from Operations 2316.10
Cash from Investing -1689.20
Cash from Financing -224.10
Net change in Cash -74.10
Free Cash Flow 2742.29
Particulars MAR 2019 (Values in Cr)
Net Income 1700.70
Cash from Operations 3000.90
Cash from Investing -550.90
Cash from Financing -2223.10
Net change in Cash -11.90
Free Cash Flow 3578.40
Company Name Price P/E P/B Market Cap 52 Week Low/High
DR. REDDY S LABORATORIES 5942.65 18.96 3.88 99134.26 4383.40 / 6505.50
BLISS GVS PHARMA LTD 109.65 13.05 1.23 1147.93 71.00 / 148.95
CIPLA LTD 1345.35 27.47 4.37 108622.88 891.30 / 1519.00
FERMENTA BIOTECH LIMITED 169.65 0.00 1.74 499.30 132.30 / 214.00
GLAXOSMITHKLINE PHARMA LT 1868.85 49.36 20.56 31659.45 1228.00 / 2649.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
DR. REDDY S LABORATORIES 5942.65 24.91 4.36 99134.26 4383.40 / 6505.50
AMRUTAJAN HEALTH LTD 637.90 41.91 7.03 1844.21 556.05 / 774.75
ASTRAZENECA PHARMA IND LT 5172.20 81.07 19.74 12930.50 3102.00 / 7208.00
BLISS GVS PHARMA LTD 109.65 16.82 1.17 1147.93 71.00 / 148.95
ABBOTT INDIA LIMITED 26131.85 48.47 17.86 55530.18 20594.25 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 6007.10
  • 26 Days 6145.00
  • 10 Days 6052.30
  • 50 Days 6173.70
  • 12 Days 6082.40
  • 100 Days 6035.40
  • 20 Days 6123.30
  • 200 Days 5228.60
6007.43
PIVOT
First Resistance 6077.22
Second Resistance 6197.28
Third Resistance 6267.07
First Support 5887.37
Second Support 5817.58
Third Support 5697.52
RSI 42.79
MACD -62.54
Commodity Channel Index (CCI) -196.67
ADX 14.15
Williams % R -85.40

Over 1 Month

down

-3.13

Over 3 Months

down

4.84

Over 6 Months

down

5.53

Over 1 Year

down

21.05

Over 3 Years

down

6.15

Over 5 Years

down

16.27

Dr. Reddy's Laboratories Future

Future: Price

25 Apr
6010.20
30 May
6050.95
27 Jun
6090.00
25 May
0 100 200 300 400 500 600

Discount/Premium

25 Apr
-5.90
30 May
34.85
27 Jun
73.90
25 May
0 1 2 3 4 5 6 7

Active Calls

6000.0
3465
6100.0
3256
6050.0
2785
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

6000.0
1391
5900.0
965
5800.0
866
25 Jul
0 500 1000 1500 2000 2500

Dr. Reddy's Laboratories Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
36.25
Promoter Holdings
26.65
FII
29.13
DII
7.95
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Aps Trust Shareholding of Promoter and Promoter Group 3.4345308E7 20.59
J P Morgan Chase Bank Na Public Shareholding 2.5608057E7 15.35
Life Insurance Corporation Of India P & Gs Fund Public Shareholding 8421089.0 5.05
Kallam Satish Reddy Huf Shareholding of Promoter and Promoter Group 5523677.0 3.31
First Sentier Investors Icvc - Stewart Investors Asia Pacific Leaders Sustainability Fund Public Shareholding 3869125.0 2.32
Nps Trust-a/c Sbi Pension Fund Scheme Tax Saver-tier 2 Public Shareholding 3838558.0 2.3
Hdfc Trustee Company Ltd. A/c Hdfc Nifty 50 Etf Public Shareholding 2705158.0 1.62
Gunupati Venkateswara Prasad Huf Shareholding of Promoter and Promoter Group 2543418.0 1.52
Sbi-etf Nifty 50 Public Shareholding 2369201.0 1.42
Government Of Singapore Public Shareholding 1708857.0 1.02
Samrajyam Reddy Kallam Shareholding of Promoter and Promoter Group 1120499.0 0.67
Satish Reddy Kallam Shareholding of Promoter and Promoter Group 901002.0 0.54
Anuradha Gunupati Shareholding of Promoter and Promoter Group 9205.0 0.01
Vsd Holdings & Advisory Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Sharathchandra Reddy Gunupati Shareholding of Promoter and Promoter Group 2600.0 0.0
K Vishal Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
K Shravya Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
Gunupati Mallika Reddy Shareholding of Promoter and Promoter Group 5139.0 0.0
G Vani Sanjana Reddy Shareholding of Promoter and Promoter Group 5140.0 0.0
Deepti Reddy Kallam Shareholding of Promoter and Promoter Group 5140.0 0.0
G V Prasad Shareholding of Promoter and Promoter Group 0.0 0.0

Dr. Reddy's Laboratories

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-07-11 40.0 Final 2023-07-12 Equity shares 2022-07-11 30.0 Final 2022-07-13 Equity shares 2021-07-09 25.0 Final 2021-07-13 Equity shares 2020-07-13 25.0 Final 2020-07-15 Equity shares 2019-07-15 20.0 Final 2019-07-17 Equity shares 2018-07-16 20.0 Final 2018-07-18 Equity shares 2017-07-17 20.0 Final 2017-07-19 Equity shares 2016-07-18 20.0 Final 2016-07-20 Equity shares 2015-07-10 20.0 Final 2015-07-14 Equity shares 2014-07-11 18.0 Final 2014-07-15 Equity shares 2013-07-12 15.0 Final 2013-07-16 Equity shares 2012-06-28 13.75 Final 2012-07-03 Equity shares 2011-06-30 11.25 Final 2011-07-05 Equity shares 2010-07-02 11.25 Final 2010-07-06 Equity shares 2009-07-03 6.25 Final 2009-07-07 Equity shares 2008-07-04 3.75 Final 2008-07-08 Equity shares 2007-07-06 3.75 Final 2007-07-10 Equity shares 2006-07-07 0.0 Final 2006-07-11 Equity shares 2005-07-07 0.0 Final 2005-07-11 Equity shares
Ex-Date Ex-Bonus Ratio
2006-08-29 2006-08-28 1:1 1994-05-03 1994-04-08 2:1
Ex-Date Old FV NEW FV Record Date
2001-10-10 10.0 5.0 2001-10-25

Learn More About Stocks

Dr Reddy's Laboratories Limited Overview

Dr. Reddy's Laboratories Ltd, an eminent pharmaceutical company based in India, offers an extensive portfolio across Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Dominating its revenue, the Global Generics Segment, constituting about 83% in FY22, includes over 400 generic drugs with significant contributions from nervous system, gastrointestinal, and anti-infective drugs. The Pharmaceutical Services & Active Ingredients (PSAI) segment, accounting for 14% of revenues, underscores its position as one of the world's largest API manufacturers, benefiting its generics business with cost competitiveness. Meanwhile, its proprietary products focus on differentiated formulations, with subsidiary Aurgene Discovery advancing novel therapeutics for cancer and inflammation. Geographically, the USA leads its revenue share at 37%, followed by India and Russia. The company boasts 23 manufacturing facilities worldwide and maintains a strategic focus on niche products, injectables, and biosimilars to enhance profitability. FY21 saw partnerships for COVID-19 treatments, including the launch of the Sputnik-V vaccine in India. Recent divestments and acquisitions, such as the portfolio from Eton Pharmaceuticals, reflect its commitment to streamlining operations and expanding its product offerings, supporting its mission to provide affordable medications globally.

About Dr. Reddy's Laboratories

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Dr. Reddy's Laboratories

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

Can I open multiple demat accounts?

Answer Field

Yes, you can open multiple demat accounts but only under the below conditions:

  • You can open only one demat account per DP using the same PAN card.
  • You can open multiple demat accounts with different DPs using the same PAN card.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking Mobile App for effortless investing and trading

Bajaj Broking App Download

6.5 Lac+ Users

icon-with-text

4.1 App Rating

icon-with-text

4 Languages

icon-with-text

₹ 3500 Cr MTF Book

icon-with-text
loader